Theravance Biopharma
901 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.theravance.com/
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
248 articles about Theravance Biopharma
-
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer
11/7/2022
Theravance Biopharma, Inc. reported financial results for the third quarter of 2022.
-
Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System
11/2/2022
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
-
Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022
10/31/2022
Theravance Biopharma, Inc. will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022.
-
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
10/25/2022
Theravance Biopharma, Inc. announced new ampreloxetine data in neurogenic orthostatic hypotension will be presented at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society, taking place November 2-5, 2022, in Maui, Hawaii.
-
Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
9/28/2022
Theravance Biopharma, Inc. announced a "modified Dutch auction" tender offer to purchase up to $95 million of its ordinary shares, par value $0.00001 per share.
-
This week's money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.
-
Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program
9/19/2022
Theravance Biopharma, Inc. announced that its Board of Directors has authorized a $250 million capital return program consisting of the following three elements.
-
Theravance Biopharma to Present at Upcoming September 2022 Investor Conferences
9/6/2022
Theravance Biopharma, Inc. will be participating in the following Fireside Chats, both of which will be webcast.
-
Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2022.
-
Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
Theravance Biopharma, Inc. will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022.
-
Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023
7/26/2022
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a tender offer (the "Offer") to purchase any and all of its outstanding 3.25% Convertible Senior Notes due 2023 (the "Convertible Notes").
-
Under the terms of the deal, Theravance and Innoviva are surrendering 85% and 15% of their stakes in Trelegy in exchange for $1.1 billion and $282 million from Royalty, respectively.
-
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
7/13/2022
Theravance Biopharma, Inc. announced it has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA to Royalty Pharma for over $1.5 billion in potential total value.
-
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2022.
-
Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022
5/2/2022
Theravance Biopharma, Inc. will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2022.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Theravance Biopharma to Participate in an Upcoming Investor Conference - Apr 06, 2022
4/6/2022
Theravance Biopharma, Inc. will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET.
-
Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results from the Ampre...
4/5/2022
Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH). -
Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)
4/4/2022
Theravance Biopharma, Inc. today announced results from the second Phase 3 study, Study 0170 (n=128 out of n=154 planned), assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic nOH. Study 0170 was a 22-week Phase 3 study comprised of a 16-week open-label period followed by a 6-week double-blind, placebo-controlled, randomized withdrawal period.
-
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/23/2022
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021.